Motif Bio to submit NDA for iclaprim
Motif Bio said the antibiotic may be suitable for first-line empiric therapy in ABSSSI patients, especially those with renal impairment, with or without diabetes. Unlike many standard of care antibiotics, iclaprim is only minimally cleared via the kidneys. No nephrotoxicity was observed with iclaprim in theĀ …